company background image
CRDL logo

Cardiol Therapeutics TSX:CRDL Stock Report

Last Price

CA$2.66

Market Cap

CA$185.9m

7D

-4.3%

1Y

125.4%

Updated

06 Oct, 2024

Data

Company Financials +

Cardiol Therapeutics Inc.

TSX:CRDL Stock Report

Market Cap: CA$185.9m

CRDL Stock Overview

A clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.

CRDL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Cardiol Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cardiol Therapeutics
Historical stock prices
Current Share PriceCA$2.66
52 Week HighCA$4.26
52 Week LowCA$0.91
Beta0.70
11 Month Change6.83%
3 Month Change2.31%
1 Year Change125.42%
33 Year Change-34.16%
5 Year Change0.38%
Change since IPO-35.90%

Recent News & Updates

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12
We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

May 01
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

Recent updates

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12
We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

May 01
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Jan 06
Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Sep 13
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

May 24
We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Jan 20
We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Aug 10
We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Apr 17
We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Dec 09
Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Aug 19
We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Apr 18
Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Jan 03
Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Shareholder Returns

CRDLCA PharmaceuticalsCA Market
7D-4.3%0.7%0.6%
1Y125.4%-1.7%23.3%

Return vs Industry: CRDL exceeded the Canadian Pharmaceuticals industry which returned -1.7% over the past year.

Return vs Market: CRDL exceeded the Canadian Market which returned 23.3% over the past year.

Price Volatility

Is CRDL's price volatile compared to industry and market?
CRDL volatility
CRDL Average Weekly Movement9.3%
Pharmaceuticals Industry Average Movement10.2%
Market Average Movement8.2%
10% most volatile stocks in CA Market17.1%
10% least volatile stocks in CA Market3.1%

Stable Share Price: CRDL has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatility Over Time: CRDL's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aDavid Elsleywww.cardiolrx.com

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.

Cardiol Therapeutics Inc. Fundamentals Summary

How do Cardiol Therapeutics's earnings and revenue compare to its market cap?
CRDL fundamental statistics
Market capCA$185.89m
Earnings (TTM)-CA$29.34m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CRDL income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$29.34m
Earnings-CA$29.34m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.42
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CRDL perform over the long term?

See historical performance and comparison